Ken Griffin’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ken Griffin’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Sell	94,000 -327,600	-78%	-$5.43M	﹤0.01%	6368
2025 Q4	$5.56M	Buy	421,600 +226,000	+116%	+$2.67M	﹤0.01%	4133
2025 Q3	$1.4M	Buy	195,600 +176,700	+935%	+$9.21M	﹤0.01%	6802
2025 Q2	$892K	Buy	18,900 +9,200	+95%	+$375K	﹤0.01%	7359
2025 Q1	$379K	Sell	9,700 -8,000	-45%	-$345K	﹤0.01%	9074
2024 Q4	$958K	Buy	17,700 +7,200	+69%	+$368K	﹤0.01%	7110
2024 Q3	$529K	Sell	10,500 -4,000	-28%	-$187K	﹤0.01%	8143
2024 Q2	$638K	Sell	14,500 -10,800	-43%	-$457K	﹤0.01%	7543
2024 Q1	$1.27M	Sell	25,300 -22,500	-47%	-$1.22M	﹤0.01%	6440
2023 Q4	$2.89M	Buy	47,800 +13,700	+40%	+$706K	﹤0.01%	4704
2023 Q3	$1.94M	Buy	+34,100	New	+$1.88M	﹤0.01%	5269

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ken Griffin's MLTX Position: Q1 2026 in Review

Ken Griffin increased its MoonLake Immunotherapeutics (MLTX) stake by 248% in Q1 2026, buying an estimated $15.6M and bringing the position to 1,323,728 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Ken Griffin first reported a position in MLTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $121M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Ken Griffin held 1,323,728 shares of MoonLake Immunotherapeutics worth $24.7M as of Q1 2026.
Ken Griffin bought 942,838 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $15.6M.
MoonLake Immunotherapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2077 holding.
Ken Griffin first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 22 quarters since.
Ken Griffin's MoonLake Immunotherapeutics position peaked at $121M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.